Although France has had a vaccination program for 40 years, since 1990, an increase in whooping cough cases with parent-infant transmission has been observed. This study prospectively assessed the frequency of Bordetella pertussis infection in adults who consulted general practitioners for a persistent cough without an evident diagnosis. Among 217 patients, 70 (32%) confirmed whooping cough cases were identified. One case was culture positive, 36 were polymerase chain reaction positive, and 40 had increases or decreases of у2-fold in anti-pertussis toxin IgG titer between serum samples collected during the acute and convalescent phases. The median duration of cough in confirmed cases was 49 days (range, 13-123 days). Of the patients, 60% reported vaccination, and 33% reported whooping cough in infancy. Pertussis should be considered for diagnosis of acute and chronic cough in adults. Future studies should evaluate the public health interest of booster doses of pertussis vaccine in adults.
the major cause of the resurgence in France was waning immunity after vaccination due to a lack of regular natural or vaccine boosters. This led the French national vaccination committee to introduce in 1998 a late booster vaccination, for children 11-13 years old to protect adolescents.
Cough is one of the most common complaints for which adult patients seek medical attention in primary care [7] . However, whooping cough is rarely mentioned among the etiologies of prolonged cough. Thus, a prospective study was conducted in Paris and the surrounding area to determine the proportion of B. pertussis infection in adults consulting general practitioners for persistent cough.
Subjects, Materials, and Methods
Subjects and sampling. Patients were recruited by 80 general practitioners (GPs) from April through December 1999. Persons eligible for this study were у18 years old, presented with persistent cough of 7-31 days duration, and had no fever, no clear cause for the cough (asthma, tuberculosis, lung cancer, superinfected chronic bronchitis with obstruction, chronic heart failure, pneumonia, or sinusitis), and were not being treated with angiotensin-converting enzyme inhibitors. Over the study period, the GPs were asked to report the total number of consultations and to record all patients with persistent cough who met the inclusion criteria, including those who were not approached to be part of the study or who were approached but refused. We estimated the size of the population served by the participating clinicians by using data on total number of GP consultations provided by the French health insurance office.
The GPs interviewed patients by using a standardized questionnaire to collect data on sociodemographic characteristics, vacci- [6] , and 1 specific for B. pertussis, Bordetella parapertussis, and Bordetella bronchiseptica species (AC-PCR) [8] , were used. In brief, NPAs were digested with proteinase K. DNA was extracted with Phenol-Tris (Interchim), and the amplification reaction was done as described elsewhere [6] .
Measurements of anti-PT IgG and IgA were done by use of an ELISA [9] and purified PT (provided by Aventis-Pasteur Laboratories). The minimum level of detection (MLD) was 2 and 1 EU/ mL for anti-PT IgG and IgA antibodies, respectively. A serum sample was considered to be positive if the number of ELISA units was у4 times the MLD. A serologically confirmed diagnosis was based either on a у2-fold increase or decrease in anti-PT IgG titers between acute and convalescence serum samples.
Case definitions. Confirmed cases were either culture or PCR positive or serologically confirmed. Noncases were enrolled cases without laboratory confirmation of B. pertussis infection by PCR or anti-PT IgG serologic tests. Unclassifiable cases had undetermined or were lacking laboratory results.
Statistics. Data analyses were performed with Epi-Info software (version 6.04; CDC). Proportions were compared by use of the x 2 test. For continuous variables, we used the Student's t and the nonparametric Kruskal-Wallis tests. Statistical significance was assessed at an a error of 0.05.
Results
In total, 217 subjects were enrolled. The median age was 49 years (range, 18-88 years). The majority of the patients were women (73%). The median duration of the cough at enrollment was 18 days (range, 7-69 days), the median of the total duration of cough was 42 days (range, 7-128 days), and 195 subjects (90%) reported a paroxysmal cough. Vaccination status was reported for 132 patients (57%) but was documented in only 46% of the patients' vaccination booklets. We found that 94% of subjects born after 1966 (generalization of vaccination) were immunized. NPAs were technically feasible for 123 samples; 183 patients provided paired serum samples, and 197 patients (91%) had 3 visits.
Infection was confirmed for 70 patients (32%). If we add the serologic data based either on a у2-fold increase or decrease in anti-PT IgA titers, the number of confirmed cases is 106 (49%). For patients for whom interval from cough onset to the first specimen collection was known ( ), the proportion n p 200 of patients with a positive PCR assay or anti-PT IgG change in titers was constant with increasing interval (table 1). The mean duration of cough was significantly shorter for unclassifiable cases (41 vs. 52 days;
), suggesting that patients P p .01 who provided NPA and paired serum samples were more likely to be infected by B. pertussis. Case distribution was not influenced by age, sex, or immigrant status.
Among the 80 participating GPs, 58 recorded exhaustively the eligible cases. They were consulted by 132,446 patients (0.49% of GP activity in the Paris area) over the 9-month study period. Considering that 8,736,201 adults live in Paris and its suburbs (according to the Institut National de la Statistique et des É tudes Economiques), the adult population served by the participating clinicians was estimated to be 42,800 patients. Among them, 710 (1.7%; 95% confidence interval [CI], 1.5%-1.8%) met the inclusion criteria, but only 99 (14%) were enrolled, and 40 (40%; 95% CI, 30%-50%) had evidence of pertussis infection. By using these data, we estimate that 284 (193-385) pertussis case patients would have consulted a participating GP over the study period, corresponding to an incidence of pertussis of 884 adult case patients/ 100,000 population (95% CI, 601-1199 adult case patients/ 100,000 population) for a 1-year period.
Of the 123 NPAs tested by PCR, 36 (29%) were positive by both PCR assays, confirming pertussis infection; 5 were positive by only the AC-PCR, confirming infection with B. pertussis, B. parapertussis, or B. bronchiseptica; 67 tested negative; and 15 were not interpretable. We performed cultures with 48 NPAs and only 1 (also PCR-positive) was positive. For 10 patients, we performed PCR assays on both NPA and sputum, and results were positive for 6 sputum samples versus 3 NPAs. The mean time interval between the start of the cough and NPA collection was similar in PCR-positive and PCR-negative subjects (20 vs. 21 days). No correlation was found between the results of PCR and previous contact with B. pertussis or antibiotic treatments.
Anti-PT IgG titers were determined for all 183 paired serum samples. Forty subjects (22%) had a serologic confirmation and 49 (27%) had positive serologic test results, without a significant increase or decrease in anti-PT IgG titers. Among serologic confirmations, 25 (63%) presented a у2-fold increase, whereas 15 (37%) presented a у2-fold decrease in anti-PT IgG titers. A decrease was more frequently observed when case patients had prior contact with B. pertussis via immunization or infection (100% vs. 65%;
), confirming results of previous P p .04 studies [9] .
Of the 49 subjects who had positive serologic test results, without significant increase or decrease in anti-PT IgG titers, 22 (45%) had a у2-fold increase or decrease in anti-PT IgA titers. Furthermore, among the 15 PCR-positive and anti-PT IgG-negative subjects, 8 (53%) presented at least a doubling or halving of anti-PT IgA titers.
The median duration of cough was 49 days for the confirmed cases and was not influenced by treatment with macrolides. The characteristics of the cough by case definition (table 2) were similar in all age groups. In all, 79% of the confirmed cases met World Health Organization (WHO) clinical criteria [10] , and 89% met Centers for Disease Control and Prevention (CDC) clinical criteria [11] . Thirty-three percent of the case patients reported a history of whooping cough, and 60% reported having received whole-cell vaccination in infancy (table  2) . For confirmed cases, previous contact with the bacterium was associated with a shorter duration of coughing (46 vs. 81 days;
). Thirty-six pertussis case patients reported con-P ! .001 tacts with a known cougher; however, their contacts were not investigated for B. pertussis infection.
Discussion
This study, conducted in a region of France with very high vaccination coverage (96% at age 12 months for primary vaccination in 1998 [12] ), shows that pertussis is more common among adults than previously thought. Our results are consistent with the recent high prevalence of whooping cough in adults with cough observed in Canada and the United States, 2 other countries with high levels of vaccination coverage [13] . The clinical symptoms are consistent with those described in the United States [13] but seem to differ from those described in Germany, a country with a lower vaccination coverage, where adult cases tended to be more typical [14] . Among French adults presenting with persistent cough, we estimated an annual incidence rate of 884 cases/100,000 population (95% CI, 601-1199 cases/100,000 population). In a recent US study [15] , the population-based incidence was 507 cases/100,000 person-years (95% CI, 307-706 cases/100,000 person-years). By using the same case definition, our estimated incidence is 508 cases/100,000 person-years, which is similar. However, our results need confirmation through a French population-based incidence study.
On the basis of a patient's self report, we observed no difference between previously vaccinated or infected adults and other case patients, suggesting that the immunity induced by whole-cell vaccination or natural infection is similar in terms of duration and that immunity following B. pertussis infection is not life-long. In all, 79% of the confirmed cases met the WHO clinical criteria, and 89% met the CDC clinical criteria [11] . However, patients with no evidence of pertussis also met a high proportion of these criteria (83% and 89%, respectively), showing that the specificity of these definitions is low for diagnosis in adults and that laboratory confirmation is essential to identify adult case patients.
Our results confirm that PCR is more efficient than culture for diagnosis. However, we only enrolled patients who had been coughing for 17 days, thereby decreasing the chances of obtaining a positive culture. During this study, we observed that NPAs of adults might contain more inhibitors than those of infants or children. Further research is needed to determine whether sputum could be used instead of NPA for adolescents and adults. Few Bordetella PCR-positive results were obtained, compared with B. pertussis PCR-positive results. This result is similar to that obtained in Finland, where B. parapertussis infection is more frequent than B. pertussis infection in young children but much lower in adults [16] . We confirmed that IgA titer determination seems to be useful for diagnosis, because 45% of the subjects who had positive IgG titers without any increase or decrease presented a у2-fold increase or decrease in IgA titers.
In conclusion, in France, where pertussis vaccination coverage has been very high for many years, we confirmed that pertussis is a cause of persistent coughing in adults and that it should be an important element in differential diagnosis of cough. The high estimated incidence of pertussis in adults suggests that adult vaccine booster may decrease the burden of illness in adults and may also prevent familial spread of disease and transmission to infants.
